We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ProtoKinetix Targets Multi Billion Dollar Stem Cell Industry
News

ProtoKinetix Targets Multi Billion Dollar Stem Cell Industry

ProtoKinetix Targets Multi Billion Dollar Stem Cell Industry
News

ProtoKinetix Targets Multi Billion Dollar Stem Cell Industry

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ProtoKinetix Targets Multi Billion Dollar Stem Cell Industry"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ProtoKinetix Inc. has announced that the Company has received from the University of Helsinki, a report confirming a major breakthrough in the storage of stem cells.

This emerging industry generated $12 Billion in revenues in 2005 and is forecasted to exceed $50 Billion in 2010. In this recent report, AAGP™ was shown to produce significant increases in stem cell viability and competence under both cryopreservation (-80°C) and at refrigeration (+4°C) temperatures.

This analysis consolidates data from previous findings and observed no conflicting observations. Using cryopreservation on a range of both mouse and human embryonic stem cell lines, there was a consistent increase in the viable yield of almost 100% (from 40% to 76%). Other tests show that 96% of the cells remain in an unaffected state indicating that the stem cells are still competent.

These findings show that AAGP™ not only increases cell viability but also maintains cell competence for future use in therapies.

This report and other research data are to be presented to the commercial stem cell storage industry.

Advertisement